Prostate cancer Trials in Prague, Czechia
Conditions / Prostate cancer / Prague, Czechia
Prostate cancer is a medical condition with active clinical research programs worldwide.
43 total trials for this combination
Showing top 10 of 43 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | COMPLETED | PHASE3 |
| NCT07028853 | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | RECRUITING | — |
| NCT07028853 | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | RECRUITING | — |
| NCT00925600 | Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss | COMPLETED | PHASE3 |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer | COMPLETED | PHASE3 |
| NCT01459653 | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor | COMPLETED | — |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | RECRUITING | — |
| NCT00626548 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer | TERMINATED | PHASE3 |
| NCT07028853 | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | RECRUITING | — |